Navigation Links
Indevus Reports Positive Data From Phase III NEBIDO Trial

Compound Achieves All Key Endpoints for Both Efficacy and Safety

LEXINGTON, Mass., June 07, 2007 /PRNewswire-FirstCall/ -- Indevus Pharmaceuticals, Inc. today announced final results from its Phase III pharmacokinetic trial for NEBIDO (testosterone undecanoate), a long- acting injectable testosterone therapy under development for the treatment of male hypogonadism which the Company licensed from Bayer Schering Pharma AG, Germany. The data from the recently completed 48-week trial showed that NEBIDO met its primary endpoints, a responder analysis based on average testosterone concentrations during the steady state dosing interval and an outlier analysis based on the maximum testosterone concentrations during the steady state dosing interval. In addition, the drug was well tolerated. The Company will host a conference call and webcast today at 9:00 a.m. eastern time (details follow below).

"I am extremely pleased to report the successful completion of our NEBIDO study and we are looking forward to the submission of our NDA later this summer," stated Glenn L. Cooper, M.D., chairman and chief executive officer of Indevus. "The market opportunity for NEBIDO is substantial. The results of our trial demonstrate the potential of NEBIDO, the only once every three month treatment for male hypogonadism, to dramatically improve the treatment options for men who suffer from this condition."

Study Design

The study was designed to supplement the European clinical trial database (originally generated by Bayer Schering Pharma AG, Germany), which has formed the basis for the approval of NEBIDO in over 75 countries to date. Specifically, the purpose of the completed Phase III trial was to evaluate NEBIDO under U.S. Food and Drug Administration (FDA) pharmacokinetic guidelines for the approval of testosterone therapy products for male hypogonadism.

The Phase III pharmacokinetic trial was a randomized op
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Indevus Announces Presentation of Pagoclone Data at 47th Annual New Clinical Drug Evaluation Unit Meeting
2. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
3. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
4. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
5. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
6. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
7. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
8. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
9. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
10. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
11. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Indevus Reports Positive Data From Phase III NEBIDO Trial
(Date:11/28/2014)... QC , Nov. 28, 2014 /CNW Telbec/ - Ergoresearch ... and known under the « Équilibre, orthèses et ... Ended on September 30, 2014. All dollar amounts in the ... for the first quarter of fiscal year 2015 ended this ... by 2,1 % compared to revenues of $ 4 227 942 ...
(Date:11/28/2014)... LOS ANGELES , Nov. 28, 2014 According ... Americans over the course of their lifetime. For many, these ... chronic pain that is caused by a variety of factors. ... disc, surgery may be the best option. While there are ... Laser Discectomy performed by Seyed M. Rezaian , M.D., ...
(Date:11/28/2014)... Nov. 28, 2014  Valeant Pharmaceuticals International, Inc. ... announced that its wholly owned subsidiary, Valeant Pharmaceuticals ... of its outstanding 6.875% Senior Notes due 2018, ... on December 29, 2014 and has mailed an ... the redemption, approximately US$500 million aggregate principal amount ...
Breaking Medicine Technology:First Quarter Results fiscal year ended September 30, 2015 - Ergoresearch reports its results for the quarter ended September 30, 2014. 2First Quarter Results fiscal year ended September 30, 2015 - Ergoresearch reports its results for the quarter ended September 30, 2014. 3First Quarter Results fiscal year ended September 30, 2015 - Ergoresearch reports its results for the quarter ended September 30, 2014. 44 Advantages of Laser Back Surgery When Fixing a Herniated Disk 2Valeant Announces Redemption of US$445.0 Million Aggregate Principal Amount of its Outstanding 6.875% Senior Notes due 2018 2
... fewer products in the pipeline and more at the ... commercial life of mature brands are critical to today,s ... as many as 10 years and billions of dollars ... To help biopharmaceutical companies more effectively ...
... Mass., Feb. 24, 2012  Haemonetics Corporation (NYSE: HAE ... Company effective March 5, 2012 as Vice President of ... ) Mr. Helsel, age 48, was with ... was Vice President of Operations for the Surgical Solutions ...
Cached Medicine Technology:Report Delivers ROI Analysis on Key Lifecycle Management Strategies Utilized by the Pharmaceutical Industry 2Dave Helsel Joins Haemonetics as Vice President of Global Manufacturing 2
(Date:11/28/2014)... York, NY (PRWEB) November 28, 2014 ... physical therapy techniques such as Dynamic Neuromuscular Stabilization, ... and gait/motion analysis. After moving to upgraded facilities ... and running clinic. Now, owner Dr. Lev Kalika ... performance and injury prevention lab in the country. ...
(Date:11/28/2014)... Agein.com, the Internet’s premier anti-aging web site focusing ... foremost experts in the industry, is releasing its top diet ... , “The official start of winter is still three weeks ... with an icy blast. After one of the worst winters ... usher in another brutal winter,” says Dr. Kevin J. McLaughlin, ...
(Date:11/28/2014)... Junk-A-Car ( http://www.junkacar.com ), one of the ... to help drivers, especially those in and around the ... areas deal with the especially harsh winter weather that ... the country. , With the high number of reported ... crashed and junk cars, Junk-A-Car is voluntarily ...
(Date:11/28/2014)... Mequon, Wisconsin (PRWEB) November 28, 2014 ... facial plastic surgeons , announced the expansion of Quintessa ... new center will be located at W307 N1497 Golf ... 2015. , According to Dr. Campbell, the new Delafield ... non-surgical procedures for patients, including: Botox, filler ...
(Date:11/28/2014)... 2014 Secura Consultants, based in ... marketing organizations in the country focused on delivering ... marketplace. Secura Consultants is proud to offer complimentary ... Group, a leading global financial company. , Many ... the ownership interest comes the need for business ...
Breaking Medicine News(10 mins):Health News:New York Dynamic Neuromuscular Rehabilitation Opens Nation's Most Advanced Movement Performance and Injury Prevention Lab 2Health News:New York Dynamic Neuromuscular Rehabilitation Opens Nation's Most Advanced Movement Performance and Injury Prevention Lab 3Health News:Agein Corporation, a Leading Anti-Aging Company, Releases Top Diet and Personal Care Tips for Preventing Dry Skin this Season 2Health News:Junk-A-Car Expanding Service to Assist U.S. Car Owners That May be Affected by Severe Winter Storms 2Health News:Dr. Andrew Campbell to Expand Quintessa Aesthetic Center into Delafield 2Health News:Secura Consultants Offers Complimentary Buy-Sell Agreement Reviews 2
... -- Some women who inherit the BRCA1 or BRCA2 breast ... with breast cancer nearly a decade earlier than those who ... Researchers examined the family trees of 128 breast or ... determine the origins of the patients, cancer genes. "No ...
... around the world are reporting they are burned out and ... Pennsylvania School of Nursing,s Center for Health Outcomes and Policy ... Between 20 to 60 percent of nurses reported ... International Journal for Quality in Health Care , which ...
... of South American songbirds completed by the Department of ... Natural History, has discovered these birds differ dramatically in ... which indicates they are on the road to becoming ... show that species could change, that they were not ...
... Copenhagen have explored the active principles of a Danish mushroom ... particularly toxic towards cancer cells. The goal is to synthesise ... in future drug development. Asia has a long ... products. Many substances found in fungi are today registered as ...
... INDIANAPOLIS -- The health care system in the United States ... to the bedside, how to ensure more equitable use of ... how to pay for that care. The 10th ... of the journal Medical Care tackles key conceptual ...
... Over the past quarter century in Australia, cancer incidence rates ... are some of the findings of a recent study published ... Compared with any other disease group, cancer has ... two Australians developing cancer and one in five dying from ...
Cached Medicine News:Health News:Family Tree May Affect Diagnosis Age in Some Breast Cancers 2Health News:To keep nurses, improve their work environments 2Health News:Danish mushroom inspires cancer researchers 2Health News:Danish mushroom inspires cancer researchers 3Health News:Journal supplement presents strategies for introducing health care delivery innovation 2Health News:Study sheds light on cancer burden in Australia 2
... Aerosol Resistant Tips offer a safe alternative ... are designed for applications such as PCR(a), ... addition, ART Tips are excellent for tissue ... studies. ART Tips prevent aerosol contaminants and ...
... LBP Processor is a primary component of ... accessioning, processing, sampling, and slide preparation ... The MonoPrep LBP Processor produces high-quality sample ... broad range of cytology specimen types. It ...
... Like all Gilson disposable ... in a sterilized version. Each ... in medical device-quality plastic to ... Sterilization is guaranteed by the ...
200 L, Racked, Pre-sterilized, 96 tips/rack Recommended for 20, 25, 50, 100 and 200 L pipettes. Can also be used with 300 L pipettes when pipetting 200 L or less....
Medicine Products: